'Supplemental figure 3' presentation slideshows

Supplemental Figure 1

Supplemental Figure 1. A B. C. Supplemental Figure 2. RWPE-1. DU-145. AR- CaP -M. PC-3. AR- CaP -E. PC-3-ML. 70 kDa. c- myc. 57 kDa. ?-actin. 42 kDa. Supplemental Figure 3. A B. Supplemental Figure 4. pPEG -Luc. pAEG -Luc. 24h 48h.

202 views • 8 slides

Antagonist (n=2,855)

197 views • 7 slides

CAMA-1

A. Supplemental Figure 1. Cyclin E. Actin. B. 10A. 76NF2V. T47D. M4A4. 76N. 76NE7. ZR75-1. MCF-7. HCC38. NM2C5. HCC-1500. MDA-MB-453 (HER2+). Full Length Cyclin E Levels. LMW-E Levels. p=0.003. Cyclin E. Actin. Densitometry Units. HCC-1937. HCC-1954. HCC-1428.

289 views • 6 slides

10 h

Supplemental Figure 1. 5 h. 10 h. 0 h. Untreated. 16 h. 14 h. 24 h.

190 views • 5 slides

AL4

A. B. Supplimental figure 1. Melanoma free survival curve (A) and summary table (B) for median survival and melanoma free survival for each genotype. All of them are Ink/Arf-/-. C. A. B. EV. Sh4. Sh11. PTEN. AL4. ECAD. NCAD. pAKT. pERK. EV. Sh4. Sh11. -. pFAK. Pten. pSTAT.

265 views • 4 slides

Supplemental Figure 1

Supplemental Figure 1. Events. Events. Events. Events. HLA-A2. CD137L. CD64. HLA-DR15. K562. Events. Events. aAPC. CD80. CD83. Supplemental Figure 2. CD3. FSC-H. FSC-A. CD14 , CD19, Vivid. SSC. CD4. CD8. FSC-A. Supplemental Figure 3. B. A. Fold expansion.

193 views • 4 slides

Supplemental Figure 3

Supplemental Figure 3. Test Set Molcules. ddb. Hydrastinine. + b hydrastine. Olopatadine. Olopatadine M1. KCNQ2. Roxithromycin. Roxithromycin M1. Roxithromycin M2. Roxithromycin M3.

109 views • 4 slides

Supplemental Figure 3

Supplemental Figure 3. B. A. NS. NS. control -shRNA. TLR2 -shRNA. control -shRNA. TLR2 -shRNA. MDS-A (low-risk). MDS-B (high-risk).

80 views • 1 slides

0.5

Supplemental Figure 3. Ngn3. HES1. Hexokinase 2. 4. 2.5. 8. 2. 3. 6. 1.5. 4. 2. 1. 2. 1. 0.5. 0. 0. 0. Ngn3-EGFP +. Ngn3-EGFP -. Ngn3-EGFP +. Ngn3-EGFP -. Ngn3-EGFP +. Ngn3-EGFP -. Insulin I. Pdx-1. MafA. 15. 2. 3. 1.5. 10. 2. 1. 5. 1. 0.5. 0. 0. 0.

126 views • 1 slides

Supplemental Figure 3

Leucine kinetics ( m mol.kg -1 .h -1 ). Leucine kinetics ( m mol.kg -1 .h -1 ). 160. 160. NS. NS. 140. 140. NS. NS. 120. 120. 100. 100. 80. 80. 60. 60. NS. **. 40. 40. 20. 20. 0. 0. Ra LEU. Ox LEU. NOLD. Ra LEU. Ox LEU. NOLD. Supplemental Figure 3.

96 views • 1 slides

- + - + - + - + (AvrBsT)

At4g22285 At4g22290 At4g22300 At4g22310. - + - + - + - + (AvrBsT).

109 views • 1 slides

Warfarin : - + + Quercetin : - - +

Supplemental Figure 3. A. B. *. *. **. *. **. **. **. *. *. *. *. Warfarin : - + + Quercetin : - - +. Warfarin : - + + Quercetin : - - +. C. Warfarin : - + + - + + - + + Quercetin : - - + - - + - - +.

227 views • 1 slides

0.01

Supplemental figure 3. 0.02 0.01 0 -0.01 -0.02. 0.03 0.02 0.01 0 -0.01 -0.02. 0.02 0.01 0 -0.01 -0.02. 0.02 0.01 0 -0.01 -0.02. 0.02 0.01 0 -0.01 -0.02. 0.02 0.01 0 -0.01 -0.02. 0.02 0 -0.02 -0.04. 0.02 0.01 0 -0.01 -0.02.

116 views • 1 slides

Supplemental Figure 3

wt apaf-1 -/- p53 -/-. Bcl-2. ERK2. C 16 24 48 C 16 24 48 C 16 24 48. TPT (h). Supplemental Figure 3.

88 views • 1 slides

Supplemental Figure:3

ATF6 ? -N. ? - tubulin. hATF6 ? -Luc. D. Supplemental Figure:3. Fold change. -. C. ERR ?. +. +. +. -. -. PGC1 ?. **. A. B. **. **. Human 2077 ggg aggtca agc 2066. Ad-GFP. **. Relative ATF6 ? mRNA level. Human 1612 gat aggtca caa 1601. Ad- shUS. Ad-GFP. Ad- shERR ?.

78 views • 1 slides

Supplemental Figure 3

Supplemental Figure 3. Control. Inhibitor treated. SNK6. NKYS. KAI3. SubG1. G2/M= 48.47%. G2/M= 72.58%. G2/M= 47.39%. G1. S. SubG1. G2/M. Fold changes in SubG1 (Control=1). Fold changes in G2/M (Control=1). SNK6. KAI3. SNK6. NKYS. KAI3. NKYS.

59 views • 1 slides

Supplemental Figure 3, Ghielmetti et al

medium. TB40/E. TB40/E-UV. Supplemental Figure 3, Ghielmetti et al.

96 views • 1 slides

SUPPLEMENTAL FIGURE 3

SUPPLEMENTAL FIGURE 3. B. A. C. D.

56 views • 1 slides

Supplemental Figure 3

Supplemental Figure 3.

70 views • 1 slides

Supplemental Figure 3

Supplemental Figure 3.

58 views • 1 slides